Enzyme-deficiency metabolic cardiomyopathies and the role of enzyme replacement therapy

Progress in Pediatric Cardiology

Volumn 23, Issue 1-2, 2007, Pages 39-48

  Kishnani, Priya S ^a   BurnsWechsler, Stephanie ^a   Li, Jennifer S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cardiomyopathy; Enzyme replacement therapy; Fabry; Lysosomal storage disease; Mucopolysaccharidoses; Pompe

Indexed keywords

AGALSIDASE BETA; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GALSULFASE; GLUCAN 1,4 ALPHA GLUCOSIDASE; INOTROPIC AGENT; LARONIDASE; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; UNCLASSIFIED DRUG;

ANAMNESIS; AORTA STENOSIS; AORTA VALVE; ARTICLE; CARDIOMYOPATHY; CLINICAL TRIAL; CORONARY CARE UNIT; DATA ANALYSIS; DEATH; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ENZYME REPLACEMENT; FABRY DISEASE; GLYCOGEN STORAGE DISEASE TYPE 2; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; LYSOSOME STORAGE DISEASE; METABOLIC CARDIOMYOPATHY; METABOLIC DISORDER; MITRAL VALVE; MITRAL VALVE REGURGITATION; MITRAL VALVE STENOSIS; MUCOPOLYSACCHARIDOSIS; NONHUMAN; OUTCOME ASSESSMENT; PR INTERVAL; PRIORITY JOURNAL; THROMBOEMBOLISM;

EID: 34547417532     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ppedcard.2007.05.005     Document Type: Article

References (71)

1. Brady R. Enzyme replacement for lysosomal diseases. Annu Rev of Med 57 (2006) 283-296
2. Desnick R. Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis 27 3 (2004) 385-410
3. Hirschhorn R., and Reuser A. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Beaudet A., Scriver C., and Sly W. (Eds). The metabolic and molecular bases of inherited disease (2001), McGraw Hill, New York 3389-3420
4. Kishnani P., and Howell R. Pompe disease in infants and children. J Pediatr 144 5 Suppl (2004) S35-S43
5. van den Hout H., Hop W., van Diggelen O., et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 112 2 (2003) 332-340
6. Ansong A., Li J., Nozik-Grayck E., et al. Electrocardiographic response to enzyme replacement therapy for Pompe disease. Genet Med 8 5 (2006) 297-301
7. Gillette PC, Nihill MR, Singer DB. Electrophysiological mechanism of the short PR interval in Pompe disease. American journal of diseases of children (1960) 1974;128(5):622-6.
8. Metzl J., Elias E., and Berul C. An interesting case of infant sudden death: severe hypertrophic cardiomyopathy in Pompe's disease. Pacing Clin Electrophysiol 22 5 (1999) 821-822
9. Bulkley B., and Hutchins G. Pompe's disease presenting as hypertrophic myocardiopathy with Wolff-Parkinson-White syndrome. Am Heart J 96 2 (1978) 246-252
10. Francesconi M., Auff E., Ursin C., and Sluga E. WPW syndrome combined with AV block 2 in an adult with glycogenosis (Type II). Wien Klin Wochenschr 94 15 (1982) 401-404
11. Ing R., Cook D., Bengur R., et al. Anaesthetic management of infants with glycogen storage disease type II: a physiological approach. Paediatr Anaesth 14 6 (2004) 514-519
12. Wang LYJ, Ross A, Li J, et al. Cardiac arrhythmias following anesthesia induction in infantile-onset Pompe disease: A case series. Paediatr Anaesth in press.
13. Wiegand V., Rumpf K., Bardosi A., Meinck H., and Kreuzer H. Hemodynamic findings in the adult form of type II glycogenosis. Z Kardiol 75 1 (1986) 44-46
14. DiFiore M., Manfredi R., Marri L., and Zucchini A. Elevation of transaminases as an early sign of late-onset glycogenosis type II. Eur J Pediatr 152 (1993) 784
15. Ausems M., Lochman P., van Diggelen O., Ploos van Amstel H., Reuser A., and Wokke J. A diagnostic protocol for adult-onset glycogen storage disease type II. Neurology 52 4 (1999) 851-853
16. An Y., Young S., Hillman S., Van Hove J., Chen Y., and Millington D. Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease. Anal Biochem 287 1 (2000) 136-143
17. Umapathysivam K., Hopwood J., and Meikle P. Determination of acid alpha-glucosidase activity in blood spots as a diagnostic test for Pompe disease. Clin Chem 47 8 (2001) 1378-1383
18. Chamoles N., Niizawa G., Blanco M., Gaggioli D., and Casentini C. Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper. Clin Chem Acta 347 1-2 (2004) 97-102
19. Niizawa G., Blanco M., Casentini C., and Borrajo G. Newborn screening for MPS1 and Pompe disease: a pre-pilot study. Mol Genet Metab 84 (2005) A202
20. Li Y., Scott C., Chamoles N., et al. Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem 50 10 (2004) 1785-1796
21. Zhang H., Kallwass H., Young S., and Carr C. A comparison of methods for lysosomal acid alpha-glucosidase activity determination from dried blood spots for diagnosis of Pompe disease. Genet Med 8 (2006) 302-306
22. Raben N., Plotz P., and Byrne B. Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med 2 2 (2002) 145-166
23. Laforet P., Nicolino M., Eymard P., et al. Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology 55 8 (2000) 1122-1128
24. Hirschhorn R., and Huie M. Frequency of mutations for glycogen storage disease type II in different populations: the delta525T and deltaexon 18 mutations are not generally "common" in white populations. J Med Genet 36 1 (1999) 85-86
25. Van der Kraan M., Kroos M., Joosse M., et al. Deletion of exon 18 is a frequent mutation in glycogen storage disease type II. Molec Cell Biol Res Commun 203 3 (1994) 1535-1541
26. Van den Hout H., Reuser A., Vulto A., Loonen M., Cromme-Dijkhuis A., and Van der Ploeg A. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 356 9227 (2000) 397-398
27. Van den Hout J., Reuser A., de Klerk J., Arts W., Smeitink J., and Van der Ploeg A. Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis 24 2 (2001) 266-274
28. Amalfitano A., Bengur A., Morse R., et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 3 2 (2001) 132-138
29. Klinge L., Straub V., Neudorf U., et al. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord 15 1 (2005) 24-31
30. Van den Hout J., Kamphoven J., Winkel L., et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113 5 (2004) e448-e457
31. Kishnani P., Nicolino M., Voit T., and Rogers R. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 149 1 (2006) 89-97
32. Kishnani P., Corzo D., Nicolino M., et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68 2 (2007) 99-109
33. Cook A., Kishnani P., Carboni M., et al. Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha glucosidase enzyme replacement therapy for Pompe disease. Genet Med 8 5 (2006) 313-317
34. Kishnani P., Steiner R., Bali D., et al. Pompe disease diagnosis and management guideline. Genet Med 8 5 (2006) 267-288
35. Desnick R., Ioannou Y., and Eng C. Alpha-galactosidase A deficiency: Fabry disease. In: Scriver C., Beaudet A., Sly W., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease (2001), McGraw-Hill, New York 3733-3774
36. Spada M., Pagliardini S., Yasuda M., et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79 1 (2006) 31-40
37. Kotanko P., Kramar R., Devrnja D., et al. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 15 5 (2004) 1323-1329
38. Rolfs A., Bottcher T., Zschiesche M., et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 366 9499 (2005) 1794-1796
39. Sachdev B., Takenaka T., Teraguchi H., et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105 12 (2002) 1407-1411
40. Chimenti C., Pieroni M., Morgante E., et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 110 9 (2004) 1047-1053
41. Pieroni M., Chimenti C., De Cobelli F., et al. Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization. J Am Coll Cardiol 47 8 (2006) 1663-1671
42. Weidemann F., Breunig F., Beer M., et al. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 26 12 (2005) 1221-1227
43. Pieroni M., Chimenti C., Ricci R., Sale P., Russo M., and Frustaci A. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 107 15 (2003) 1978-1984
44. Linhart A., Lubanda J., Palecek T., et al. Cardiac manifestations in Fabry disease. J Inherit Metab Dis 24 Suppl 2 (2001) 75-83 [discussion 65]
45. Shah J., and Elliott P. Fabry disease and the heart: an overview of the natural history and the effect of enzyme replacement therapy. Acta Paediatr Suppl 94 447 (2005) 11-14 [discussion 9-0]
46. Kampmann C., Wiethoff C., Perrot A., Beck M., Dietz R., and Osterziel K. The heart in Anderson Fabry disease. Z Kardiol 91 10 (2002) 786-795
47. Eng C., Guffon N., Wilcox W., et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 345 1 (2001) 9-16
48. Thurberg B., Rennke H., Colvin R., et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62 6 (2002) 1933-1946
49. Banikazemi M., Bultas J., Waldek S., et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146 2 (2007) 77-86
50. Weidemann F., Breunig F., Beer M., et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 108 11 (2003) 1299-1301
51. Beck M., Ricci R., Widmer U., et al. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Investig 34 12 (2004) 838-844
52. Spinelli L., Pisani A., Sabbatini M., et al. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clin Genet 66 2 (2004) 158-165
53. Elleder M., Poupetova H., and Kozich V. Fetal pathology in Fabry's disease and mucopolysaccharidosis type I. Ceskoslov Patol 34 1 (1998) 7-12
54. Neufeld E., and Muenzer J. The mucopolysaccharidoses. In: Scriver C., Beaudet A., Sly W., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease (2001), McGraw-Hill, New York 3421-3452
55. Dangel J. Cardiovascular changes in children with mucopolysaccharide storage diseases and related disorders-clinical and echocardiographic findings in 64 patients. Eur J Pediatr 157 7 (1998) 534-538
56. Wippermann C., Beck M., Schranz D., Huth R., Michel-Behnke I., and Jungst B. Mitral and aortic regurgitation in 84 patients with mucopolysaccharidoses. Eur J Pediatr 154 2 (1995) 98-101
57. Mohan U., Hay A., Cleary M., Wraith J., and Patel R. Cardiovascular changes in children with mucopolysaccharide disorders. Acta Paediatr 91 7 (2002) 799-804
58. Roubicek M., Gehler J., and Spranger J. The clinical spectrum of alpha-l-iduronidase deficiency. Am J Med Genet 20 3 (1985) 471-481
59. Muenzer J. The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. J Pediatr 144 5 Suppl (2004) S27-S34
60. Muenzer J., and Fisher A. Advances in the treatment of mucopolysaccharidosis type I. N Engl J Med 350 19 (2004) 1932-1934
61. Kakkis E., Muenzer J., Tiller G., et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 344 3 (2001) 182-188
62. Wraith J., Clarke L., Beck M., et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-l-iduronidase (laronidase). J Pediatr 144 5 (2004) 581-588
63. Wraith J. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother 6 3 (2005) 489-506
64. Wraith JE, Beck M, Lane R, et al. Enzyme replacement therapy in Mucopolysaccharidosis I patients less than 5 years old: results of a multinational study of recombinant human α-l-Iduronidase (laronidase). Pediatrics in press.
65. Braunlin E., Berry J., and Whitley C. Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I. Am J Cardiol 98 3 (2006) 416-418
66. Vinallonga X., Sanz N., Balaguer A., Miro L., Ortega J., and Casaldaliga J. Hypertrophic cardiomyopathy in mucopolysaccharidoses: regression after bone marrow transplantation. Pediatr Cardiol 13 2 (1992) 107-109
67. Gatzoulis M., Vellodi A., and Redington A. Cardiac involvement in mucopolysaccharidoses: effects of allogeneic bone marrow transplantation. Arch Dis Child 73 3 (1995) 259-260
68. Harmatz P., Giugliani R., Schwartz I., et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 148 4 (2006) 533-539
69. Muenzer J., Wraith J., Beck M., et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8 8 (2006) 465-473
70. Muenzer J., Lamsa J., Garcia A., Dacosta J., Garcia J., and Treco D. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatr Suppl 91 439 (2002) 98-99
71. Harmatz P., Ketteridge D., Giugliani R., et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 115 6 (2005) e681-e689